Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in IndiaDo Indian households face distress health financing?

In India, a cancer diagnosis doesn't just threaten your life — it threatens everything your family owns. Nearly four in five households hospitalized for cancer in 2014 spent more than ten percent of everything they consumed that year on that single hospital stay. Anshul Kastor and Sanjay K. Mohanty set out to map that financial devastation, disease by disease and rupee by rupee. What they found reshapes how we should think about who bears the true cost of getting sick. India's health financing system runs largely on what economists call out-of-pocket expenditure, or OOPE. This is money paid directly by patients at the point of care, not covered by insurance or government programs. Two-thirds of all health spending in India flows this way. That's not a minor quirk of the system; it's the system. Unlike insurance or tax-funded models, out-of-pocket costs hit hardest precisely when households are least able to absorb them — during illness, when income may be falling and expenses are spiking simultaneously. Kastor and Mohanty used data from the National Sample Survey Organization's seventy-first round, collected across India in the first half of 2014. The dataset covered sixty-five thousand nine hundred thirty-two households and more than three hundred thirty-three thousand individuals, with forty-two thousand eight hundred sixty-nine hospitalization episodes available for analysis. They tracked three measures of financial harm. First, OOPE: hospital spending minus any reimbursement received. Second, catastrophic health expenditure, or CHE: defined as OOPE exceeding ten percent of a household's total consumption expenditure for the year — the threshold at which medical bills start crowding out food, education, and basic needs. Third, distress financing: when a household has to borrow money, sell property or other assets, or rely on contributions from friends and relatives just to cover the bill. These three measures form a chain — high OOPE can trigger CHE, which often forces distress financing. Kastor and Mohanty estimated each one separately for sixteen disease groups, arranged into three broad categories: communicable diseases, non-communicable diseases, and injuries. The overall numbers are stark enough on their own. Mean OOPE for a single hospitalization was INR nineteen thousand two hundred ten. But that average conceals enormous variation. Cancer imposed the highest mean OOPE at INR fifty-seven thousand two hundred thirty-two — nearly three times the national average. Heart disease came second at INR forty thousand nine hundred forty-seven. Injuries ran to INR twenty-five thousand three, while tuberculosis hospitalizations cost a mean of INR thirteen thousand one hundred four, and diarrhea, at the low end, just INR five thousand four hundred seventy-three. A central driver of these gaps is where people seek care. Private hospital OOPE averaged INR twenty-six thousand four hundred seven — roughly three and a half times the INR seven thousand five hundred eighty-three recorded in public facilities. For cancer, the contrast is extreme: private hospitals charged a mean of INR seventy-six thousand three hundred seventy-five versus INR twenty-eight thousand two hundred eighty-one in public hospitals. Reimbursement provided almost no buffer. On average, only five point seven percent of total hospital spending was reimbursed, and the rate was lower in public facilities than in private ones. Socioeconomic gradients run through every disease. Urban residents paid INR twenty-four thousand one hundred seven on average versus INR sixteen thousand five hundred fifty-eight in rural areas. The richest third of households by monthly per capita consumption spent a mean of INR thirty thousand three hundred seventy on hospitalization, compared with INR twelve thousand three hundred ninety-one for the poorest third. But here's the structural tension embedded in these numbers: richer households pay more in absolute terms, yet the CHE measure is a share of consumption. So the poorer households spending less in rupees can still be pushed over the catastrophic threshold far more easily. Their spending, though smaller, represents a larger slice of everything they have. Non-communicable diseases drove the bulk of the financial burden. Mean OOPE for non-communicable disease hospitalizations was INR twenty-eight thousand six hundred one, nearly three times the INR ten thousand six hundred twenty-three for communicable diseases. Cancer stays were also the longest, averaging nearly fifteen days, which compounds costs over time. Now for the crisis numbers. Across all hospitalized households, forty-nine percent incurred CHE — spending that exceeded the ten percent of consumption threshold. About twenty-eight percent both incurred CHE and reported distress financing. For cancer, the CHE rate hit seventy-nine percent. Let that sink in: in almost eight out of ten cancer hospitalizations, the family's hospital bill consumed more than a tenth of everything they spent in an entire year. Distress financing for cancer reached forty-three percent, and among those cancer households that resorted to distress financing, ninety-one percent also met the CHE threshold. The two measures aren't just correlated — for cancer, they are nearly synonymous. Cancer wasn't the only disease pushing households over the edge. More than one-third of inpatients with heart disease, neurological disorders, genitourinary problems, musculoskeletal diseases, gastrointestinal problems, or injuries reported distress financing. Tuberculosis — a communicable disease, not a non-communicable disease — still drove distress financing in roughly thirty percent of cases, demonstrating that this isn't exclusively a chronic disease problem. The logistic regression makes the structural drivers clear. Compared with diarrhea as the reference condition, cancer raised the adjusted odds of distress financing by a factor of three point two three. Tuberculosis had an odds ratio of two point six one, heart disease two point four three. Seeking care in a private hospital more than doubled the odds of distress financing, with an adjusted odds ratio of two point three. The broad non-communicable disease category had odds one point five five times those of communicable diseases; injuries ran at one point six five. While wealthier households were protected, the richest tertile had adjusted odds of distress financing thirty-four percent lower than the poorest. However, that protection was partial and disease-dependent. The structural picture that emerges is consistent and sobering. High OOPE, catastrophic expenditure, and distress financing concentrate along three axes: disease type, with cancer and heart disease at the extreme; provider type, with private hospitals amplifying costs at every level; and socioeconomic position, with poorer households reaching the catastrophic threshold at lower absolute spending. These three axes interact. A poor rural household with a cancer patient who ends up in a private hospital — often because public facilities lack capacity or specialist care — faces compounding disadvantages at every turn. The fact that seventy-six percent of households reporting distress financing also met the CHE threshold tells you something important. These two measures are capturing the same underlying crisis through different lenses. Borrowing money or selling land isn't a separate financial problem from catastrophic health spending — it is the household's response to catastrophic health spending. The chain runs from illness to high bills to asset depletion, and for diseases like cancer, it runs almost inevitably. Kastor and Mohanty's policy argument follows directly from this structure. If financial harm concentrates in specific diseases and specific provider settings, generic reforms to average health spending won't reach the households that need protection most. Their recommendations are targeted: explicitly include cancer, heart disease, and other high-cost conditions in insurance benefit packages, which current schemes largely do not. The Rashtriya Swasthya Bima Yojana, one of India's main government insurance programs, offered cashless cover of only INR thirty thousand per family per year at the time of this study — a figure that barely dents a mean cancer OOPE of INR fifty-seven thousand two hundred thirty-two. They call for free treatment for vulnerable groups for cancer and heart disease, as has been done for tuberculosis, and for risk pooling mechanisms financed jointly by households and government to socialize costs before they cascade into asset sales. Their final point is methodological, and it matters. Aggregate health spending data, the kind that reports a national average OOPE of INR nineteen thousand two hundred ten, is nearly useless for targeting interventions. It is only when you disaggregate by disease that you can see a seventy-nine percent CHE rate for cancer sitting inside that average, or a forty-three percent distress financing rate. Disease-level analysis is not a research refinement; it transforms a general concern about health spending into a navigable map of where financial catastrophe is actually happening — and therefore where protection needs to go. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.